Simple modifications of L-arginine (NG-allyl and NG-cyclopropyl derivatives) can produce potent reversible and irreversible inhibitors of inducible nitric oxide synthase.
Answers are grounded in this paper and cite their sources.
These arginine analogs support iNOS inhibitor lead development; should not change clinical practice without further evidence.
NG-Methyl-L-arginine has recently been shown to inactivate the inducible murine macrophage nitric oxide (.NO) synthase (Olken, N. M.; Rusche, K. M.; Richards, M. K.; Marletta, M. A. Biochem. Biophys. Res. Commun. 1991, 177, 828-833). NG-Allyl-L-arginine and NG-cyclopropyl-L-arginine were synthesized as potential mechanism-based enzyme inhibitors to exploit the chemistry presumed to occur at the active site. NG-Cyclopropyl-L-arginine was found to be a potent reversible inhibitor with a Ki = 7.7 microM. NG-Allyl-L-arginine was found to be both a potent reversible (Ki = 2.1 microM) and irreversible inhibitor of the enzyme. This irreversible inhibition demonstrated pseudo-first-order inactivation kinetics with kinact = 0.026 min-1 and KI = 3.4 microM. Stereospecific protection of the inactivation was afforded by L-arginine, and saturability of the inactivation rate was observed. Our studies indicate that both reversible and irreversible inhibition of the inducible .NO synthase can be achieved with relatively simple modifications of the substrate L-arginine.
No takes yet. Share an insight, caveat, or question.
Olken et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: